CyberKnife radiation for certain pancreatic cancer patients after chemotherapy
Part of Cancer, Digestive system clinical trials.
This trial studies how safe CyberKnife is when used to treat some borderline resectable or locally advanced pancreatic cancers after chemotherapy. It may help patients by targeting the tumor with precise radiation, while researchers closely watch for side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are able to sign consent and understand the study steps
- You finished a chemotherapy treatment plan before joining the trial
- You are 18 years or older
- Your general health is good enough (ECOG 0 to 1)
- Your pancreatic cancer is stage I to III and has no spread to distant organs
- Your tumor can be treated with radiation (IMRT or SBRT) and your tumor team agrees
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies a procedure called NanoKnife IRE for pancreatic cancer that cannot be removed surgically after standard chemotherapy or radiation. It uses electric pulses to destroy tumor cells and may be an option for patients who have completed other treatments.
This trial tests a very focused type of radiation (SBRT) for people with pancreatic cancer that hasn't spread to other organs but can't be removed with surgery. It may be an option if you are medically unable to have surgery or choose not to.
This trial tests whether adding a precise, high-dose radiation boost (CyberKnife) after standard chemoradiation can improve outcomes for people with stage III non-small cell lung cancer that cannot be surgically removed. It is for those who have already completed two cycles of induction chemo and at least 40 Gy of radiation with chemo.
This study tests a new approach for locally advanced pancreatic cancer that hasn't spread. It combines precise high-dose radiation with an experimental immunotherapy (PCX12) injected directly into the tumor to see if it's safe and tolerable.
This trial tests a combination of targeted radiation and two oral drugs (defactinib and avutometinib) for people with advanced pancreatic cancer that hasn't spread to distant organs. It may be an option if you've already had at least 2 months of chemo and your cancer is still locally advanced or borderline resectable.
This trial studies how well radiation therapy works for pancreatic cancer that is locally advanced (near important blood vessels) and cannot be removed with surgery. It may help shrink or control the cancer when surgery isn’t an option.
Hear when a new Pancreas Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.